| Clinical data | |
|---|---|
| Other names | 5-Methoxy-N-methyl-(α,N-trimethylene)tryptamine; CP-108509; CP108509 |
| Drug class | Serotonergic psychedelic;Hallucinogen |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C15H20N2O |
| Molar mass | 244.338 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
5-MeO-MPMI (developmental code nameCP-108509), also known as5-methoxy-N-methyl-(α,N-trimethylene)tryptamine, is apsychedelic drug of thepyrrolidinylmethylindole andcyclized tryptamine families.[1]
5-MeO-MPMI producespsychedelic-appropriate responding inanimal tests, with similarpotency toDOI.[1] It has twoenantiomers, with only the (R)-enantiomer being active.[1]
Analogues of 5-MeO-MPMI includeMPMI,4-HO-MPMI,5-fluoro-MPMI,5-MeO-pyr-T,CP-122288,CP-135807, andeletriptan, among others.
5-MeO-MPMI was first developed by the team led by J. E. Macor and colleagues in 1992.[2] It was subsequently investigated by the team led byDavid E. Nichols fromPurdue University in the late 1990s.[1]